Published in the open-access journal Biomedicine & Pharmacotherapy, this article highlights the dual mechanism of FTX-101 and its potential as a first-in-class remyelinating therapy.

Find and its FTX-101 program gain visibility through a publication in the March 2025 issue of Nature Biotechnology, a magazine with international reach.